grant
A network approach to interrogate cellular plasticity and drug resistance in cancer
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 15 Jun 2024Deadline 31 May 2029
NIHUS FederalResearch GrantFY20251-Phosphatidylinositol 3-KinaseAcetatesAdjuvantAfter CareAfter-TreatmentAftercareAnti-Cancer AgentsAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsBenchmarkingBest Practice AnalysisBiological MarkersBiologyBiometricsBiometryBiostatisticsBladderBladder Urinary SystemBody TissuesCDDPCRISPRCRISPR interferenceCRISPR-dCas9-mediated repressionCRISPR/Cas systemCRISPR/dCas9 interferenceCRISPR/dCas9-mediated transcriptional inhibitionCRISPRiCancer BurdenCancer Causing AgentsCancer DrugCancer TreatmentCancersCandidate Disease GeneCandidate GeneCarcinogensCarcinomaCell BodyCellsCessation of lifeChemicalsCis-diammine-dichloroplatinumCis-diamminedichloridoplatinumCis-diamminedichloro Platinum (II)Cis-dichloroammine Platinum (II)Cis-platinous Diamine DichlorideCis-platinum IICis-platinum II Diamine DichlorideCisplatinCisplatinaCisplatinumClinical OncologyClustered Regularly Interspaced Short Palindromic RepeatsClustered Regularly Interspaced Short Palindromic Repeats interferenceCollaborationsComplexComputing MethodologiesCredentialingCutaneous Squamous Cell CarcinomaCysplatynaDMBADNA AlterationDNA Sequence AlterationDNA mutationDataData BasesDatabasesDeathDevelopmentDichlorodiammineplatinumDistantDrug TargetingDrug TherapyDrug resistanceDrugsElementsEnvironmentEpidermoid CarcinomaEpidermoid Skin CarcinomaEpithelial cancerEsophagusExposure toGene TargetingGene TranscriptionGenesGeneticGenetic AlterationGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGenetics-MutagenesisGenomicsGenotoxinsGoalsHead and NeckHead and neck structureHouse miceHumanImmuneImmune mediated therapyImmunesImmunologically Directed TherapyImmunotherapeutic agentImmunotherapyIn SituIndividualInduction TherapyKnowledgeLungLung Respiratory SystemMalignant CellMalignant Epithelial NeoplasmsMalignant Epithelial TumorsMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMedicationMetastasisMetastasis InductionMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMethodsMiceMice MammalsModelingModern ManMolecularMurineMusMus musculusMutagenesisMutagenesis Molecular BiologyMutagensMutationNEOADJNational Cancer BurdenNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNeoplasm MetastasisNeoplastic Disease Chemotherapeutic AgentsOncogenicOncogensOncologyOncology CancerOperative ProceduresOperative Surgical ProceduresPD-1 antibodyPD1 antibodyPI-3 KinasePI3-KinasePI3CGPI3KGammaPI3kPIK3PIK3CGPIK3CG genePapillomaPathway interactionsPeyrone's ChloridePeyrone's SaltPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPhorbolsPhosphatidylinositol 3-KinasePhosphatidylinositol-3-OH KinasePhosphoinositide 3-HydroxykinasePlanocellular CarcinomaPlatinum DiamminodichloridePlayPopulationPreventionProcessProgenitor CellsProtocolProtocols documentationPtdIns 3-KinaseRNA ExpressionRadiationRadiation therapyRadiotherapeuticsRadiotherapyResectedResistance developmentResistant developmentResolutionRoleSamplingSecondary NeoplasmSecondary TumorSequence AlterationSignal PathwaySiteSkinSolid NeoplasmSolid TumorSquamous CarcinomaSquamous Cell EpitheliomaSquamous cell carcinomaStructureSurgicalSurgical InterventionsSurgical ProcedureSystemTechnologyTestingTherapeuticTissuesTranscriptionTumor CellTumor PromotionTumor-Specific Treatment AgentsType I Phosphatidylinositol KinaseType III Phosphoinositide 3-KinaseWorkaPD-1aPD1analytical toolanti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-cancer druganti-cancer therapyanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyantiPD-1benchmarkbio-computationbio-computingbio-markersbiocomputationbiocomputingbiologic markerbiomarkerbiomarker discoverycancer biomarkerscancer cellcancer drug resistancecancer markerscancer metastasiscancer therapycancer-directed therapychemical carcinogenesischemotherapycis dichlorodiammineplatinumcis platinum compoundcis-Diaminedichloroplatinumcis-Diamminedichloroplatinumcis-Diamminedichloroplatinum(II)cis-Dichlorodiammineplatinum(II)cis-Platinumcombinatorialcomparativecomputational methodologycomputational methodscomputer based methodcomputer methodscomputing methoddata basedata sharingdevelop drug resistancedeveloping resistancedevelopmentaldigitaldimethylbenz(a)anthracenedimethylbenzanthracenedrug developmentdrug interventiondrug resistance developmentdrug resistantdrug treatmentdrug/agentepithelial carcinomagenome mutationgenome scalegenome-widegenomewidegenomic alterationgenotoxic agentimmune drugsimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunotherapeuticsimmunotherapy agentin vivoin vivo Modelinduction therapiesknock-downknockdownmalignancymouse modelmurine modelnanostringneoplasm/cancerneoplastic cellnew approachesnew technologynotchnotch proteinnotch receptorsnovelnovel approachesnovel strategiesnovel strategynovel technologiesoncogenic agentpathwaypharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspost treatmentpreventpreventingradiation treatmentrepressing CRISPR-dCas9 systemresistance to Drugresistance to cancer drugsresistance to therapyresistant to Drugresistant to cancer drugsresistant to therapyresolutionsresponseresponse to therapyresponse to treatmentscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell analysissingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingskin squamous cell carcinomasocial rolespatial relationshipstandard of carestem cellssurgerytherapeutic resistancetherapeutic responsetherapeutic targettherapy resistanttherapy responsetooltranscriptomicstreatment resistancetreatment responsetreatment responsivenesstreatment with radiationtumortumor cell metastasistumor initiationurinary bladdervalidation studiesαPD-1αPD1
Description preview
ABSTRACT
We will address a critical problem in clinical oncology, namely how highly heterogeneous, drug resistant tumor
cell populations develop, and how they can be targeted. Most tumors develop resistance to almost every type
of therapy, including targeted-, radiation-, chemo- or immunotherapy, ultimately leading to cancer deaths. It is…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click